We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
- Authors
Geisbert, Thomas W; Feldmann, Heinz
- Abstract
The filoviruses, Marburg virus and Ebola virus, cause severe hemorrhagic fever with a high mortality rate in humans and nonhuman primates. Among the most-promising filovirus vaccines under development is a system based on recombinant vesicular stomatitis virus (rVSV) that expresses a single filovirus glycoprotein (GP) in place of the VSV glycoprotein (G). Importantly, a single injection of blended rVSV-based filovirus vaccines was shown to completely protect nonhuman primates against Marburg virus and 3 different species of Ebola virus. These rVSV-based vaccines have also shown utility when administered as a postexposure treatment against filovirus infections, and a rVSV-based Ebola virus vaccine was recently used to treat a potential laboratory exposure. Here, we review the history of rVSV-based vaccines and pivotal animal studies showing their utility in combating Ebola and Marburg virus infections.
- Publication
The Journal of infectious diseases, 2011, Vol 204 Suppl 3, pS1075
- ISSN
1537-6613
- Publication type
Journal Article
- DOI
10.1093/infdis/jir349